Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Caladrius Biosciences is a biotechnology business based in the US. Caladrius Biosciences stocks (CLBS.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.64 – an increase of 7.32% over the previous week. Caladrius Biosciences employs 27 staff and has a market cap (total outstanding stock value) of $25.7 million.
Finder's Pick for
Beginners
Finder's Pick for
Free Trades
Finder's Pick for
Commodity Stocks
Finder's Pick for
US Stocks
| Latest market close | $0.44 |
|---|---|
| 52-week range | $0.40 - $1.68 |
| 50-day moving average | $0.66 |
| 200-day moving average | $0.94 |
| Wall St. target price | $8.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.50 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $0.44 from 2022-05-13
| 1 week (2022-05-10) | 4.76% |
|---|---|
| 1 month (2022-04-13) | -37.14% |
| 3 months (2022-02-17) | -42.84% |
| 6 months (2021-11-17) | -57.28% |
| 1 year (2021-05-17) | -70.47% |
|---|---|
| 2 years (2020-05-15) | -75.96% |
| 3 years (2019-05-16) | 3.1 |
| 5 years (2017-05-16) | 5.37 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -27.3% |
| Return on equity TTM | -44.21% |
| Profit margin | 0% |
| Book value | $1.54 |
| Market capitalisation | $25.7 million |
TTM: trailing 12 months
We're not expecting Caladrius Biosciences to pay a dividend over the next 12 months.
Caladrius Biosciences's shares were split on a 1:10 basis on 27 July 2016. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Caladrius Biosciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Caladrius Biosciences shares which in turn could have impacted Caladrius Biosciences's share price.
Over the last 12 months, Caladrius Biosciences's shares have ranged in value from as little as $0.402 up to $1.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Caladrius Biosciences's is 0.9725. This would suggest that Caladrius Biosciences's shares are less volatile than average (for this exchange).
Caladrius Biosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc.
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
Read more…
Here’s what you need to know about investing in the propane industry, including 3 popular propane stocks to watch.
Read more…
Using our proprietary algorithm, we’ve found the best blue chip stocks on the TSX, NYSE and Nasdaq based on price, performance and more.
Read more…Everything we know about the Hanover Bancorp, Inc. IPO, plus information on how to buy in.
Everything we know about the PrimeBlock IPO, plus information on how to buy in.
Everything we know about the Actelis Networks IPO, plus information on how to buy in.
Everything we know about the ProFrac Holding Corp IPO, plus information on how to buy in.
Everything we know about the Wytec International IPO, plus information on how to buy in.
Here are some of the best stocks for inflation periods to reduce the negative impacts of inflation on your portfolio.
Choose from many account and investment types to invest in global markets, but expect to pay high commissions with HSBC InvestDirect, which doesn’t have an app.
Our Flahmingo review tells you how to buy fractional shares of some of your favourite US companies with as little as $1.
Steps to owning and managing EXPD stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing PRU stock, with 24-hour and historical pricing before you buy.
